undamentalytics Newsletter
Sign in

Gilead Sciences (GILD) stock

Add to watchlist

Add holding +

NASDAQ: GILD Nasdaq Biotechnology Next results ~February 9, 2027

B Fundamentals grade

Gilead Sciences is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$170

Cash-flow model

Base case. Range ~$120–$230 across our lower- and higher-growth cases (0.4%–10.4% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 1% above our base value.

Price used: $170.33, November 2, 2026

Gilead Sciences valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Gilead Sciences files

10-Q filed October 30: Gilead Sciences

Gilead's revenue reached $31.0bn over the twelve months to September 2026, an increase of 6.5% on the prior year and an acceleration from the 5.5% pace recorded a quarter earlier. Free-cash-flow margin climbed to 44.5%, up sharply from 31.5% a year earlier. Operating margin told a different story, narrowing to -7.6% from 36.1%. Taken together, these shifts push the fundamentals grade from C+ to B. Our model value, however, is little changed, sitting at $140 a share against a current price of $161. With the shares still trading above that estimate, the rating stays at Hold.

Source: 10-Q filed October 30, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Gilead Sciences stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $30.5bn, up 5.5% on a year earlier, faster than 3.5% a quarter earlier. Free-cash-flow margin rose to 42.5% from 32.5% a year earlier. Operating margin narrowed to -8.2% from 27.9%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 6 financial-health checks. Our cash-flow model value is $127 a share, against a share price of $155.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~February 9, 2027 (estimated)

Gilead Sciences's trailing-twelve-month revenue grew 6.5% year on year, with a free-cash-flow margin of 44.5%. Where it stands out: free-cash-flow margin of 44.5% ranks 8 of 176 biotechnology companies we cover. Where it lags: long-term debt as % of assets of 46.3% ranks 69 of 78 biotechnology companies we cover.

Our discounted-cash-flow model values the business at ~$170 per share in the base case (~$120–$230 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Net margin compressing: TTM net margin fell to -12.5%, down 40.3pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Strong cash generation. 44.5% of revenue turned into free cash flow, against a median of -145.4% for biotechnology companies we cover.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Loss-making. Operating margin is -7.6%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 43.7 points on a year ago.
  • Insiders selling. 7 insiders sold $92M of stock over the past 365 days and none bought (99% under pre-set trading plans).
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 46.3% ranks 69 of 78 biotechnology companies we cover (median 20.6%).

Latest results: FY2026 Q3

Filed October 30, 2026
Earnings per share
$2.55 against an average estimate of $2.19: beat by 16.2%
Revenue
$8.30bn, up 6.8% on a year earlier
Share reaction
+7.2% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Guidance given
product sales $31,000m to $31,300m (full year 2026); product sales excluding Veklury $30,700m to $31,000m (full year 2026)
Next report
October 29, 2026; average EPS estimate $2.03

Gilead Sciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.2%
  • 1 week+7.3%
  • 1 month+17.7%
  • This year+41.3%
  • 1 year+45.7%
  • 5 years+201.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$31B
Operating margin
-7.6%
Net margin
-12.5%
EPS (TTM, diluted)
$-3.09

Growth

Revenue growth
+6.5%
Change in growth rate
+1.0 pts
Share count change
−0.7%

Cash

Free cash flow (TTM)
$13.8B
FCF margin
44.5%
Stock pay % of revenue
2.9%

Earnings

Last results
October 29, 2026
Next results (est.)
February 9, 2027

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Insider trade
  3. Insider trade
  4. Results
  5. Guidance
  6. Deal
  7. Announcement
  8. Announcement
  9. Results
  10. Insider trade
  11. Announcement
  12. Partnership
  13. Announcement
  14. Insider trade
  15. Regulatory
  16. Insider trade
  17. Product
  18. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Gilead Sciences valuation models and calculator

What the price is pricing in

The share price implies about 5.7% a year of cash-flow growth for five years.That is close to the 2.6% a year revenue growth Gilead Sciences has delivered.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in5.7%
  • Last 12 months6.5%
  • 3 years a year4.2%
  • 5 years a year2.6%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($170.68, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$170
Price used
$170.68close November 3, 2026
Implied change
▼ 1%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Gilead Sciences's free cash flow after stock-based pay with after-tax interest added back ($11.3B, FY2026 Q3 TTM), growing 5.1% and 5.9% in the next two years (forecasts, guidance and its record), then back to 5.4% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$120–~$230 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Gilead Sciences's free cash flow after stock-based pay ( $11.3B, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Gilead Sciences as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.78 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$170 ~$120–$230 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$120 ~$110–$240 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$14 ~$11–$18 Left out: out of range vs price (0.08x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$15 ~$14–$17 Left out: out of range vs price (0.09x)
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$150 ~$120–$170 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Gilead Sciences with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −27%
  • Revenue growth 5 points higher ▲ +35%
  • Free-cash-flow margin 1 point lower ▼ −2%
  • Last year's free-cash-flow margin change, if it persists ▲ +42%
  • Discount rate 1 point higher ▼ −16%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $115$162$224$306$413$550
8.5% $84$118$163$222$298$396
10% $66$92$127$171$229$304

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$69.88$50.60$52.10$46.93$50.63$47.23$61.38$75.89$74.37$88.27$120.57$170.33
Market value$106.3bn$68.7bn$68.7bn$61.4bn$64.6bn$59.7bn$77.5bn$95.8bn$93.6bn$110.8bn$151.3bn$212.9bn
+ Net debt (− = net cash)$9.3bn$18.1bn$26.0bn$9.4bn$13.0bn$25.4bn$21.4bn$19.8bn$18.9bn$16.7bn$17.4bn$19.8bn
Enterprise value$115.6bn$86.8bn$94.7bn$70.8bn$77.6bn$85.1bn$98.8bn$115.6bn$112.5bn$127.5bn$168.7bn$232.7bn
Multiples
Price / sales 3.3x2.3x2.6x2.8x2.9x2.4x2.8x3.5x3.5x3.9x5.1x6.9x
Price / earnings 5.9x5.1x14.8x11.3x12.0xn/m12.4x20.9x16.5xn/m17.8x—
Price / free cash flow 5.2x4.2x6.1x8.2x7.8x7.9x7.2x11.5x12.6x10.7x16.0x15.5x
EV / EBITDA 5.2x4.9x6.6x8.4x17.1x19.5x9.6x15.1x14.1x62.4x16.2x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

79 /100

Strong moat

How hard Gilead Sciences's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 24.7% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 78.4%, moving by 2.2 percentage points (standard deviation) across 10 years.

  • Durability 9 / 20

    Operating margin has been a median 26.1%; its worst year was -7.6%.

  • Cash conversion 20 / 20

    Free cash flow was positive in 10 of 10 years, at a median 34.9% of revenue.

  • Discipline 16 / 20

    The diluted share count fell 1.0% over five years; stock-based pay has been a median 2.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (84 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.45 −106% $30.8bn +5%
Next $9.91 +2302% $32.9bn +7%

Next year's EPS estimate has moved +3.1% in 90 days, across 26 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −40.3% on 90 days ago. In the last 30 days, 6 analysts raised Gilead Sciences's forecast and 1 cut it.

Consensus EPS forecast Gilead Sciences, last 90 days
−$5.00 $0.00 $5.00 $10.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.75 Current fiscal year, 60 days ago: −$0.42 Current fiscal year, 30 days ago: −$0.43 Current fiscal year, 7 days ago: −$0.40 Current fiscal year, Now: −$0.45 −$0.45 Next fiscal year, 90 days ago: $9.62 Next fiscal year, 60 days ago: $9.89 Next fiscal year, 30 days ago: $9.89 Next fiscal year, 7 days ago: $9.98 Next fiscal year, Now: $9.91 $9.91

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.75$9.62
60 days ago −$0.42$9.89
30 days ago −$0.43$9.89
7 days ago −$0.40$9.98
Now −$0.45$9.91

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $2.19 $2.55 +16.2%
Jun 2026 −$7.25 −$6.75 +6.9%
Mar 2026 $1.91 $2.03 +6.2%
Dec 2025 $1.81 $1.86 +2.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 29, 2026
  • Product sales full year 2026 $31,000m to $31,300m Raised
    “Product sales $ 31,000 $ 31,300 Previously $30,100 to $30,400” source
  • Product sales excluding Veklury full year 2026 $30,700m to $31,000m Raised
    “Product sales excluding Veklury $ 30,700 $ 31,000 Previously $29,800 to $30,100” source
  • Diluted loss per share full year 2026 $-4.40 to $-4.05 GAAP Lowered
    “Diluted loss per share $ (4.40) $ (4.05) Previously $(3.75) to $(3.40)” source
  • Non-GAAP diluted loss per share full year 2026 $-1.20 to $-0.85 Non-GAAP Lowered
    “Non-GAAP diluted loss per share $ (1.20) $ (0.85) Previously $(0.65) to $(0.30)” source
  • GAAP projected product gross margin full year 2026 about 79% GAAP Maintained vs about 79
    “GAAP projected product gross margin ~ 79.0% ~ 79.0% ~ 79.0% ~ 79.0%” source
  • Non-GAAP projected product gross margin full year 2026 about 87% Non-GAAP Maintained vs about 87
    “Non-GAAP projected product gross margin ~ 87.0% ~ 87.0% ~ 87.0% ~ 87.0%” source
Show 5 more items
  • Veklury full year 2026 about $300m Maintained
    “Veklury ~ $300 Unchanged” source
  • GAAP projected operating income (loss) full year 2026 $-3,150m to $-2,750m GAAP Lowered vs -1,000m to -500m
    “GAAP projected operating income (loss) $11,400 - $11,900 $(1,000) - $(500) $(2,250) - $(1,850) $(3,150) - $(2,750)” source
  • Non-GAAP projected operating income full year 2026 $2,000m to $2,400m Non-GAAP Lowered vs 2,400m to 2,900m
    “Non-GAAP projected operating income $13,800 - $14,300 $2,400 - $2,900 $2,900 - $3,300 $2,000 - $2,400” source
  • GAAP projected effective tax rate full year 2026 -55% to -50% GAAP Raised vs -220 to -150
    “GAAP projected effective tax rate ~ 21% ~ (150%) - (220%) ~ (80%) - (90%) ~ (50%) - (55%)” source
  • Non-GAAP projected effective tax rate full year 2026 165% to 220% Non-GAAP Raised vs 140 to 190
    “Non-GAAP projected effective tax rate ~ 20% ~ 190% - 140% ~ 140% - 115% ~ 220% - 165%” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Gilead Sciences's revenue by +5.1% next year and +5.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+4.5%, weight 48%) , management guidance (+5.8%, weight 31%) and the company's own record (+5.4%, weight 21%) . How the weights are set.

Analyst recommendations

28 analysts, Oct 2026
Buy2279%
Hold518%
Sell14%

Monthly trend

  1. Oct 2026616528
  2. Sep 2026616528
  3. Aug 2026616629
  4. Jul 2026616729

Counts of recommendations published by analysts covering Gilead Sciences, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.6%
of tradable shares
Days to cover
3.4
at average volume
Short interest, 1 month
+11%
to October 15, 2026
Held by institutions
92%
of shares
Held by insiders
0.1%
of shares
Employees
17,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +45.7%

$116.90 on October 31, 2025 to $170.33

ThenNowEffect
Revenue (last 12 months) $28.9bn $30.5bn +5.5%
P/S multiple 5.1x 7.0x +37.2%
Share count 1259m 1251m +0.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +129.5%

$74.23 on November 3, 2023 to $170.33

ThenNowEffect
Revenue (last 12 months) $27.4bn $30.5bn +11.2%
P/S multiple 3.4x 7.0x +104.6%
Share count 1261m 1251m +0.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
GILD+30%+24%−2%+19%+37%+41%
Industry peers (median)−36%−57%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
GILD58%33%42%67%67%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
GILD−10%−20%−14%−27%−17%−22%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 40% from November 2, 2015 to December 24, 2018. Getting back needed a 66% gain, reached on November 25, 2022, 1432 days after the low.

Price behaviour

52-week range
$115.30 – $170.68
From 52-week high
−0.2%
vs 50-day average
+12.7%
vs 200-day average
+22.6%
Volatility (1 year)
27%
Beta vs S&P 500
0.26

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±4.1%
After a week
7 up, 4 down
typical move ±4.1%
After a month
7 up, 4 down
typical move ±6.3%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 +7.2% −2.1% — —
August 4, 2026 +0.5% +1.6% +3.5% +14.1%
May 7, 2026 −3.6% +0.5% −3.1% −6.0%
February 10, 2026 +2.7% −0.3% +0.7% −4.3%
October 30, 2025 +1.1% −0.8% +4.1% +4.9%
August 7, 2025 +8.3% +0.7% +7.9% +5.1%
April 24, 2025 −3.0% +2.8% −2.9% +0.9%
February 11, 2025 +8.2% −0.2% +12.7% +18.7%
November 6, 2024 +8.5% +3.3% +2.7% +2.1%
August 8, 2024 −0.5% +2.8% +0.5% +7.0%
April 25, 2024 −2.5% +0.6% −2.6% −2.1%
February 6, 2024 −3.0% +1.1% −4.1% −4.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Gilead Sciences’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Implied vs realised volatility

Options look rich

Option prices imply clearly more movement than the shares have shown. That strengthens the case for selling options.

  • Implied is 1.40× the last 60 days’ realised volatility , richer than 84% of the 229 stocks we screen today.
  • Why: implied is 1.40x 60-day realised, above 1-year realised, and in the top 20% of our coverage today.

Our rule for “rich”: implied at least 1.2× 60-day realised (beyond measurement noise), above 1-year realised (not just a calm spell), and in the top 20% of our coverage that day. Never with results inside the option’s life. These are our conventions, built on research showing option prices usually imply more movement than follows, most when the gap is wide. How we judge this.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

GILD Gilead Sciences Grade B $171.11

Own 100 shares, sell the $175 call expiring November 27, 2026 (25 days) for $3.45 a share — $345 per contract.

Previous session · Bid $3.45, ask $4.35, quoted Mon 2 Nov, 17:24 New York time with GILD at $171.11. Option prices move with the shares: check the live chain at your broker before trading.

  • If GILD ends below $175: you keep your shares and the $345 — 2.0% extra on the position, 29.4% a year at that pace.
  • If it ends above $175: your shares are sold at $175, a total return of 4.3% including the premium — at or above our value of ~$170.
$734 $0 −$3.4k Break-even $167.66 Our value $170 Price $171.11
Profit or loss per contract at expiry, by share price (including the shares bought at today's price).
Premium
$345
Annualised
29.4%
Break-even
$167.66
Max gain
$734
Chance of selling
~43%

Collar

Own the shares, buy the $160 put and sell the $180 call, both expiring December 18, 2026 (46 days).

  • Net cost of $0.55 a share ($55.00 per contract of 100 shares).
  • Worst case at expiry: -6.8%, if the shares fall below $160 (-6.5% from today).
  • Best case at expiry: +4.9%, if the shares rise above $180 (+5.2%); gains beyond that go to the call buyer.

Offered because the shares trade at or above our fair value of $170: a way to hold on with a floor under the price, paid for by giving up upside the model does not expect. Strikes near 25-delta; the put at its ask and the call at its bid. Protection has a cost over time: research on protective puts finds they have usually lowered returns.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Gilead Sciences in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Gilead Sciences
$27B $28B $29B $30B $31B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $27.1B Revenue (TTM), FY24 Q1: $27.5B Revenue (TTM), FY24 Q2: $27.8B Revenue (TTM), FY24 Q3: $28.3B Revenue (TTM), FY24 Q4: $28.8B Revenue (TTM), FY25 Q1: $28.7B Revenue (TTM), FY25 Q2: $28.9B Revenue (TTM), FY25 Q3: $29.1B Revenue (TTM), FY25 Q4: $29.4B Revenue (TTM), FY26 Q1: $29.7B Revenue (TTM), FY26 Q2: $30.5B Revenue (TTM), FY26 Q3: $31B $31B

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $27.1B
FY24 Q1 $27.5B
FY24 Q2 $27.8B
FY24 Q3 $28.3B
FY24 Q4 $28.8B
FY25 Q1 $28.7B
FY25 Q2 $28.9B
FY25 Q3 $29.1B
FY25 Q4 $29.4B
FY26 Q1 $29.7B
FY26 Q2 $30.5B
FY26 Q3 $31B
Revenue growth, TTM YoY Gilead Sciences
-2% 0% 2% 4% 6% 8% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -0.6% Revenue growth, TTM YoY, FY24 Q1: 1.5% Revenue growth, TTM YoY, FY24 Q2: 1.5% Revenue growth, TTM YoY, FY24 Q3: 3.3% Revenue growth, TTM YoY, FY24 Q4: 6.0% Revenue growth, TTM YoY, FY25 Q1: 4.7% Revenue growth, TTM YoY, FY25 Q2: 3.8% Revenue growth, TTM YoY, FY25 Q3: 2.8% Revenue growth, TTM YoY, FY25 Q4: 2.4% Revenue growth, TTM YoY, FY26 Q1: 3.5% Revenue growth, TTM YoY, FY26 Q2: 5.5% Revenue growth, TTM YoY, FY26 Q3: 6.5% 6.5%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -0.6%
FY24 Q1 1.5%
FY24 Q2 1.5%
FY24 Q3 3.3%
FY24 Q4 6.0%
FY25 Q1 4.7%
FY25 Q2 3.8%
FY25 Q3 2.8%
FY25 Q4 2.4%
FY26 Q1 3.5%
FY26 Q2 5.5%
FY26 Q3 6.5%
Operating margin (TTM) Gilead Sciences
-20% 0% 20% 40% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 28.0% Operating margin (TTM), FY24 Q1: 5.7% Operating margin (TTM), FY24 Q2: 9.2% Operating margin (TTM), FY24 Q3: 2.9% Operating margin (TTM), FY24 Q4: 5.8% Operating margin (TTM), FY25 Q1: 28.6% Operating margin (TTM), FY25 Q2: 27.9% Operating margin (TTM), FY25 Q3: 36.1% Operating margin (TTM), FY25 Q4: 34.0% Operating margin (TTM), FY26 Q1: 34.9% Operating margin (TTM), FY26 Q2: -8.2% Operating margin (TTM), FY26 Q3: -7.6% -7.6%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 28.0%
FY24 Q1 5.7%
FY24 Q2 9.2%
FY24 Q3 2.9%
FY24 Q4 5.8%
FY25 Q1 28.6%
FY25 Q2 27.9%
FY25 Q3 36.1%
FY25 Q4 34.0%
FY26 Q1 34.9%
FY26 Q2 -8.2%
FY26 Q3 -7.6%
FCF margin (TTM) Gilead Sciences
20% 25% 30% 35% 40% 45% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 27.4% FCF margin (TTM), FY24 Q1: 28.8% FCF margin (TTM), FY24 Q2: 24.8% FCF margin (TTM), FY24 Q3: 33.3% FCF margin (TTM), FY24 Q4: 35.8% FCF margin (TTM), FY25 Q1: 34.3% FCF margin (TTM), FY25 Q2: 32.5% FCF margin (TTM), FY25 Q3: 31.5% FCF margin (TTM), FY25 Q4: 32.1% FCF margin (TTM), FY26 Q1: 34.4% FCF margin (TTM), FY26 Q2: 42.5% FCF margin (TTM), FY26 Q3: 44.5% 44.5%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 27.4%
FY24 Q1 28.8%
FY24 Q2 24.8%
FY24 Q3 33.3%
FY24 Q4 35.8%
FY25 Q1 34.3%
FY25 Q2 32.5%
FY25 Q3 31.5%
FY25 Q4 32.1%
FY26 Q1 34.4%
FY26 Q2 42.5%
FY26 Q3 44.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Gilead Sciences took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $29.4B
  2. Cost of revenue $6.2B · 21.2%
  3. Gross profit $23.2B · 78.8%
  4. Research and development $5.8B · 19.7%
  5. Selling, general and admin $5.8B · 19.6%
  6. Other operating costs $1.6B · 5.5%
  7. Operating income $10B · 34.0%
  8. Income tax $1.3B · 4.4%
  9. Interest and other $226M · 0.8%
  10. Net income $8.5B · 28.9%

Shares of revenue. Source: Gilead Sciences's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 7.0 7.9 8.4 9.7 11.2 24.9 32.6 30.4 26.1 22.1 22.4 24.7 27.3 27.3 27.1 28.8 29.4 31.0
Gross profit — — — — — — — 26.1 21.7 17.3 17.8 20.1 20.7 21.6 20.6 22.5 23.2 24.8
EBITDA 3.6 4.0 3.9 4.1 4.6 15.4 22.4 17.8 14.4 8.4 4.5 4.4 10.2 7.7 8.0 2.0 10.4 −1.9
Operating income 3.5 4.0 3.8 4.0 4.5 15.3 22.2 17.6 14.1 8.2 4.3 4.1 9.9 7.3 7.6 1.7 10.0 −2.4
Net income 2.6 2.9 2.8 2.6 3.1 12.1 18.1 13.5 4.6 5.5 5.4 0.1 6.2 4.6 5.7 0.5 8.5 −3.9
Diluted EPS $1.41 $1.66 $1.77 $1.64 $1.81 $7.35 $11.91 $9.94 $3.51 $4.17 $4.22 $0.10 $4.93 $3.64 $4.50 $0.38 $6.78 −$3.09
Growth (year on year)
Revenue +31.4% +13.4% +5.5% +15.7% +15.5% +122.2% +31.1% −6.9% −14.1% −15.2% +1.5% +10.0% +10.6% −0.1% −0.6% +6.0% +2.4% +6.5%
EBITDA +31.6% +12.1% −4.2% +6.0% +13.0% +232.6% +45.3% −20.3% −19.4% −41.3% −46.1% −4.0% +135.1% −25.3% +4.0% −74.3% +408.7% −117.9%
Operating income +31.8% +12.3% −4.4% +5.8% +12.8% +237.4% +45.4% −20.5% −19.9% −41.9% −47.7% −5.0% +143.6% −26.1% +3.8% −78.1% +503.0% −122.5%
Net income +33.2% +10.1% −3.4% −7.5% +18.6% +293.5% +49.6% −25.4% −65.7% +17.9% −1.3% −97.7% — −26.2% +23.4% −91.5% — −147.6%
Diluted EPS +36.9% +17.7% +6.6% −7.3% +10.4% +306.1% +62.0% −16.5% −64.7% +18.8% +1.2% −97.6% — −26.2% +23.6% −91.6% — −148.0%
Margins
Gross margin — — — — — — — 86.0% 83.3% 78.1% 79.2% 81.5% 75.8% 79.3% 76.0% 78.3% 78.8% 79.9%
EBITDA margin 51.3% 50.7% 46.1% 42.2% 41.3% 61.8% 68.5% 58.6% 55.0% 38.1% 20.2% 17.7% 37.5% 28.1% 29.4% 7.1% 35.3% −6.3%
Operating margin 50.3% 49.8% 45.2% 41.3% 40.4% 61.3% 68.0% 58.0% 54.1% 37.1% 19.1% 16.5% 36.3% 26.9% 28.0% 5.8% 34.0% −7.6%
Net margin 37.6% 36.5% 33.4% 26.7% 27.5% 48.6% 55.5% 44.4% 17.7% 24.7% 24.0% 0.5% 22.8% 16.8% 20.9% 1.7% 28.9% −12.5%
Free-cash-flow margin 40.6% 34.9% 41.8% 28.8% 26.5% 49.3% 62.8% 53.6% 43.3% 33.8% 37.1% 30.5% 39.6% 30.6% 27.4% 35.8% 32.1% 44.5%
Cash flow
Cash from operations 3.1 2.8 3.6 3.2 3.1 12.8 21.3 17.0 11.9 8.4 9.1 8.2 11.4 9.1 8.0 10.8 10.0 14.5
Capital spending 0.2 0.1 0.1 0.4 0.1 0.6 0.7 0.7 0.6 0.9 0.8 0.7 0.6 0.7 0.6 0.5 0.6 0.7
Free cash flow 2.8 2.8 3.5 2.8 3.0 12.3 20.5 16.3 11.3 7.5 8.3 7.5 10.8 8.3 7.4 10.3 9.5 13.8
Stock-based pay 0.2 0.2 0.2 0.2 0.3 0.4 0.4 0.4 0.6 0.8 0.6 0.6 0.6 0.6 0.8 0.8 0.9 0.9
Free cash flow after stock pay 2.7 2.6 3.3 2.6 2.7 11.9 20.1 15.9 10.7 6.6 7.7 6.9 10.2 7.7 6.7 9.5 8.6 12.9
Balance sheet
Cash 1.3 0.9 9.9 1.8 2.1 10.0 12.9 8.2 7.6 17.9 11.6 6.0 5.3 5.4 6.1 10.0 7.6 6.4
Total debt 1.2 4.1 7.6 8.2 6.6 12.4 22.2 26.3 33.5 27.3 24.6 31.4 26.7 25.2 25.0 26.7 24.9 26.2
Net debt (negative = net cash) −0.1 3.2 −2.3 6.4 4.5 2.4 9.3 18.1 26.0 9.4 13.0 25.4 21.4 19.8 18.9 16.7 17.4 19.8
Diluted shares 1,868m 1,747m 1,580m 1,583m 1,695m 1,647m 1,521m 1,358m 1,319m 1,308m 1,277m 1,263m 1,262m 1,262m 1,258m 1,255m 1,255m 1,250m
Returned to shareholders
Dividends — — — — 0.0 0.0 1.9 2.5 2.7 3.0 3.2 3.4 3.6 3.7 3.8 3.9 4.0 4.1
Buybacks 1.0 4.0 2.4 0.7 0.6 5.3 10.0 11.0 1.0 2.9 1.7 1.6 0.5 1.4 1.0 1.2 1.9 1.4
Total returned 1.0 4.0 2.4 0.7 0.6 5.3 11.9 13.5 3.7 5.9 5.0 5.0 4.2 5.1 4.8 5.1 5.9 5.5

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 6 checks passed · September 30, 2026
What it owns · $51.4bn
Short-term assets $16.6bnLonger-term assets $34.9bn
What it owes, and who funded it · $25.0bn
Short-term liabilities $12.0bnShareholders' equity $13.0bn
  • Short-term assets cover short-term liabilities $16.6bn of assets due within a year against $12.0bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $6.4bn of cash against $26.2bn of debt.
  • Debt below 40% of shareholders' equity Debt is 201% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 126% to 201% over five years.
  • A year's operating cash flow covers at least 20% of debt $14.5bn of operating cash flow against $26.2bn of debt.
  • Operating profit covers interest at least five times over Operating income of −$2.4bn against $1.0bn of interest.

From Gilead Sciences's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$1.4B
Dividends (TTM)
$4.1B
Returned to shareholders
40%
of free cash flow
Buybacks, last 3 fiscal years
$4.1B
Diluted share count
−0.7%
year over year
Total shareholder yield
2.6%
dividends 1.9% + buybacks 0.7% of market value
R&D spending
20.4%
of revenue
Sales & admin spending
22.0%
of revenue
Days sales outstanding
59 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated GILD AMGN REGN ABBV VRTX BIIB Median
Revenue, last 12 months $31.0bn $38.1bn $16.9bn $64.4bn $12.6bn $10.3bn $56m
Revenue growth, last 12 months 6.5% 9.1% 18.6% 10.4% 10.2% 2.3% 12.6%
Revenue growth, 3-year average 4.2% 12.7% 8.9% 4.7% 9.8% 1.0% 13.7%
Revenue growth, latest quarter 6.8% 9.5% 36.3% 10.2% 12.5% 10.6% 10.2%
Gross margin 79.9% 69.5% — 71.5% 86.0% 74.0% 82.9%
Operating margin −7.6% 30.0% 28.8% 26.2% 38.0% 22.9% −189.4%
Operating margin, 3-year average 10.4% 24.5% 27.8% 22.4% 23.0% 34.4% −363.5%
Net margin −12.5% 23.0% 28.5% 9.8% 35.0% 3.4% −169.8%
Cash from operations / revenue 46.7% 32.8% 28.7% 30.3% 34.1% 21.8% −168.0%
Free-cash-flow margin 44.5% 26.7% 22.6% 28.3% 30.2% 20.1% −162.4%
Free-cash-flow margin, 3-year average 36.4% 24.9% 25.7% 30.6% 16.5% 21.1% −310.0%
Stock pay / revenue 2.9% 1.3% 5.9% 1.5% 5.5% 3.0% 20.0%
Change in share count −0.7% 0.2% −3.2% 0.0% −0.6% 1.2% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 6.5% 12.6% 102 of 172
Change in growth rate Growth +1.0pp -0.1pp 74 of 172
Gross margin Profitability 79.9% 82.4% 41 of 75
Operating margin Profitability -7.6% -189.4% 43 of 175
Net margin Profitability -12.5% -157.3% 48 of 180
Free-cash-flow margin Cash generation 44.5% -145.4% 8 of 176
Stock pay as % of revenue Cash generation 2.9% 19.2% 18 of 179
Long-term debt as % of assets Balance sheet 46.3% 20.6% 69 of 78
Change in share count Balance sheet -0.7% 7.9% 16 of 156
Days sales outstanding Balance sheet 59 days 75 days 42 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Products $28.9B ▲ 1.1%
HIV Product Sales $20.8B ▲ 5.8%
HIV Products Biktarvy $14.3B ▲ 6.8%
Oncology Product $3.2B ▼ 1.6%
Liver Disease $3.2B ▲ 6.5%
HIV Products Descovy $2.8B ▲ 30.5%
Cell Therapy Products Total Cell Therapy Product Sales $1.8B ▼ 6.8%
HIV Products Genvoya $1.5B ▼ 15.0%
Other Products Yescarta $1.5B ▼ 4.8%
Trodelvy $1.4B ▲ 6.2%
Liver Disease Products Sofosbuvir Velpatasvir $1.3B ▼ 20.3%
HIV Products Odefsey $1.2B ▼ 9.4%
Liver Disease Products Vemlidy $1.1B ▲ 11.6%
Veklury $911M ▼ 49.4%
Liver Disease Products Other Liver Disease $874M ▲ 87.2%
Other Products Total Other Product Sales $799M ▼ 10.1%
Royalty Contract and Other $527M ▲ 266.0%
Other Products Am Bisome $509M ▼ 4.5%
HIV Products Other HIV $500M ▲ 15.2%
HIV Products Symtuza Revenue Share $495M ▼ 16.4%
Cell Therapy Products Tecartus $344M ▼ 14.6%
Other Products Other $290M ▼ 18.5%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
United States $20.9B 70.9% ▲ 1.4%
Europe $5.1B 17.2% ▲ 9.3%
Rest of World $3.5B 11.9% ▼ 0.7%

From Gilead Sciences's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$141B
Institutions reporting
2,269
Shares held vs prior quarter
▲ 2.3%
Positions opened / closed
115 / 163

Top buyers and sellers, Q2 2026: 1,066 institutions bought and 1,014 sold ; the biggest buyer was Assenagon Asset Management S.A (+4.1M shares) and the biggest seller Jpmorgan Chase & Co (−13.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $15.4B 121.8M 10.9% ▲ 2.4%
Vanguard Capital Management LLC $10.2B 81.1M 7.3% ▲ 0.5%
FMR LLC $8.4B 66.9M 6.0% ▼ 7.0%
State Street Corp $7.7B 61.2M 5.5% ▲ 2.3%
Capital World Investors $5.2B 41.0M 3.7% ▼ 0.7%
Invesco Ltd. $5B 39.8M 3.6% ▼ 4.2%
Vanguard Portfolio Management LLC $4.5B 35.3M 3.2% ▲ 0.5%
Geode Capital Management, LLC $3.8B 30.1M 2.7% ▲ 1.1%
Price T Rowe Associates Inc $3.8B 30.0M 2.7% ▲ 14.3%
Morgan Stanley $3B 24.0M 2.2% ▲ 3.0%
Dodge & Cox $3B 23.7M 2.1% ▼ 2.4%
Norges Bank $2.8B 22.0M 2.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Gilead Sciences's complete shareholder register. Values are as reported by the filers ; 6 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $92M 83 trades by 7 insiders · 99% under pre-set plans
Net ▼ $92M net selling
Insider Date Trade Shares Price Value
O'Day Daniel Patrick Chairman & CEO November 2, 2026 Sell pre-set plan 2,000 $171.06 $342,125
O'Day Daniel Patrick Chairman & CEO November 2, 2026 Sell pre-set plan 7,796 $170.35 $1.3M
O'Day Daniel Patrick Chairman & CEO November 2, 2026 Sell pre-set plan 1,904 $169.27 $322,296
O'Day Daniel Patrick Chairman & CEO November 2, 2026 Sell pre-set plan 1,700 $168.10 $285,771
O'Day Daniel Patrick Chairman & CEO November 2, 2026 Sell pre-set plan 1,600 $167.40 $267,840
O'Day Daniel Patrick Chairman & CEO October 30, 2026 Sell pre-set plan 15,881 $175.25 $2.8M
Mercier Johanna Chief Comm & Corp Aff Officer October 15, 2026 Sell pre-set plan 3,000 $156.22 $468,660
Dickinson Andrew D Chief Financial Officer October 15, 2026 Sell pre-set plan 3,000 $156.22 $468,660
O'Day Daniel Patrick Chairman & CEO October 1, 2026 Sell pre-set plan 3,000 $148.63 $445,880
O'Day Daniel Patrick Chairman & CEO October 1, 2026 Sell pre-set plan 12,000 $147.72 $1.8M
Mercier Johanna Chief Comm & Corp Aff Officer September 15, 2026 Sell pre-set plan 600 $145.29 $87,174
Mercier Johanna Chief Comm & Corp Aff Officer September 15, 2026 Sell pre-set plan 800 $144.46 $115,566

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 82 trades and filings

In the last 12 months, 2 members of Congress disclosed 3 purchases and 0 sales of Gilead Sciences shares.

  • Jared Moskowitz(D-FL 23):Purchase, $1,001 - $15,000, traded May 6, 2026, filed June 19, 2026
  • Jared Moskowitz(D-FL 23):Purchase, $1,001 - $15,000, traded May 6, 2026, filed June 19, 2026
  • Josh Gottheimer(D-NJ 5):Purchase, $1,001 - $15,000, traded January 27, 2026, filed February 26, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around February 9, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • August 4, 2026
  • May 7, 2026
  • February 10, 2026
  • October 30, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Gilead Sciences was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Gilead Sciences in brief

What does Gilead Sciences do?
Gilead Sciences is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Gilead Sciences's stock ticker?
Gilead Sciences trades under the ticker GILD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Gilead Sciences's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Gilead Sciences reported revenue of $31B, 6.5% higher than a year earlier, according to its SEC filings.
What is Gilead Sciences's free cash flow?
Gilead Sciences's free-cash-flow margin is 44.5% of revenue over the trailing twelve months, ranking 8 of the 176 biotechnology companies we cover.
What is Gilead Sciences's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Gilead Sciences's free cash flow after stock-based pay gives ~$170 per share in the base case, and ~$120–$230 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Gilead Sciences's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and FMR LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Gilead Sciences buying back stock, and does it pay a dividend?
Gilead Sciences spent $1.4B on share repurchases over the trailing twelve months, and its diluted share count fell 0.7% over the year.
What is Gilead Sciences's market cap?
On November 2, 2026, Gilead Sciences's market capitalisation was about $213B and net debt of $19.8B. Market figures come from third-party market data and may be delayed.
Does Gilead Sciences pay a dividend?
Yes: Gilead Sciences paid $4.1B in dividends over the trailing twelve months, a dividend yield of 1.94%.
How much debt does Gilead Sciences have?
Gilead Sciences's debt-to-equity ratio is 201.2%, from its latest balance sheet (126.4% five years earlier). The financial health section below sets out its other solvency checks.
Who are Gilead Sciences's competitors?
In our Biotechnology peer group, the companies closest to Gilead Sciences are Amgen, Regeneron Pharmaceuticals, AbbVie, Vertex Pharmaceuticals and Biogen. The side-by-side comparison below sets their revenue, margins and growth against Gilead Sciences's.
Are insiders buying or selling Gilead Sciences stock?
Over the last 12 months, Gilead Sciences's directors and officers reported 0 open-market purchases and 83 sales on Form 4. The insider trading page charts every trade.
When is Gilead Sciences's next earnings date?
Around February 9, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Gilead Sciences announces its own schedule.